Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma

Journal of Clinical Oncology

Volumn 31, Issue 16, 2013, Pages

  Diamond, Jennifer R ^a   Salgia, Ravi ^b   Varella Garcia, Marileila ^a   Kanteti, Rajani ^b   LoRusso, Patricia M ^c   Clark, Jeffrey W ^d   Xu, Ling Guo ^a   Wilner, Keith ^e   Eckhardt, S Gail ^a   Ching, Keith A ^e   Lira, Maruja E ^e   Schoenmakers, Eric F P M ^e   Christensen, James G ^e   Camidge, D Ross ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN 7; ENMD 2076; PF 04217903; PHOSPHOTRANSFERASE INHIBITOR; SCATTER FACTOR RECEPTOR; SUNITINIB; TEMSIROLIMUS; THREONINE; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG; 2-(4-(3-QUINOLIN-6-YLMETHYL-3H-(1,2,3)TRIAZOLO(4,5-B)PYRAZIN-5-YL)PYRAZOL-1-YL)ETHANOL; 2 (4 (3 QUINOLIN 6 YLMETHYL 3H (1,2,3)TRIAZOLO(4,5 B)PYRAZIN 5 YL)PYRAZOL 1 YL)ETHANOL; METHIONINE; PROTEIN TYROSINE KINASE; PYRAZINE DERIVATIVE; RON PROTEIN; TRIAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; CASE REPORT; CHROMOSOME 7; CHROMOSOME DUPLICATION; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DNA ISOLATION; DNA SEQUENCE; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPH NODE DISSECTION; MALE; NEPHRECTOMY; PAPILLARY CARCINOMA; PAPILLARY RENAL CELL CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOMATIC MUTATION; THROMBECTOMY; TUMOR THROMBUS; BIOPSY; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; HETEROZYGOTE; KIDNEY TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; POINT MUTATION; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HETEROZYGOTE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KIDNEY NEOPLASMS; MALE; METHIONINE; MIDDLE AGED; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-MET; PYRAZINES; RECEPTOR PROTEIN-TYROSINE KINASES; SEQUENCE ANALYSIS, DNA; THREONINE; TREATMENT FAILURE; TRIAZOLES;

MLCS; MLOWN;

EID: 84880695425     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.4289     Document Type: Article

References (25)

1. Motzer RJ, Bacik J, Mariani T, et al: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20:2376-2381, 2002
2. Reuter VE, Presti JC Jr: Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 27:124-137, 2000
3. Chow WH, Devesa SS: Contemporary epidemiology of renal cell cancer. Cancer J 14:288-301, 2008
4. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
5. Krishnaswamy S, Kanteti R, Duke-Cohan JS, et al: Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 15:5714-5723, 2009
6. Pitts TM, Tan AC, Kulikowski GN, et al: Development of an integrated genomic classifier for a novel agent in colorectal cancer: Approach to individualized therapy in early development. Clin Cancer Res 16:3193-3204, 2010
7. Lubensky IA, Schmidt L, Zhuang Z, et al: Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 155:517-526, 1999
8. Schmidt L, Duh FM, Chen F, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73, 1997
9. Maritano D, Accornero P, Bonifaci N, et al: Two mutations affecting conserved residues in the Met receptor operate via different mechanisms. Oncogene 19:1354-1361, 2000
10. Jeffers M, Schmidt L, Nakaigawa N, et al: Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 94:11445-11450, 1997
11. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
12. Rodig SJ, Shapiro GI: Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs 11:1477-1490, 2010
13. Durante C, Russo D, Verrienti A, et al: XL184 (cabozantinib) for medullary thyroid carcinoma. Expert Opin Investig Drugs 20:407-413, 2011
14. Eder JP, Shapiro GI, Appleman LJ, et al: A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 16:3507-3516, 2010
15. Jin H, Yang R, Zheng Z, et al: MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 68:4360-4368, 2008
16. Giordano S: Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer. Curr Opin Mol Ther 11:448-455, 2009
17. Wen PY, Schiff D, Cloughesy TF, et al: A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol 13:437-446, 2011
18. Rosen PJ, Sweeney CJ, Park DJ, et al: A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 16:2677-2687, 2010
19. Gordon MS, Sweeney CS, Mendelson DS, et al: Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 16:699-710, 2010
20. Cecchi F, Rabe DC, Bottaro DP: Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 46:1260-1270, 2010
21. Yap TA, Olmos D, Brunetto AT, et al: Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29:1271-1279, 2011
22. Kollmannsberger CK, Hurwitz H, Vlahovic G: Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265-101). J Clin Oncol 27:68e, 2011 (suppl; abstr e14525)
23. Eder JP, Vande Woude GF, Boerner SA, et al: Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207-2214, 2009
24. Katayama R, Khan TM, Benes C, et al: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 108:7535-7540, 2011
25. Doebele RC, Pilling AB, Aisner DL, et al: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18:1472-1482, 2012